Any feedback?
Literature summary for 1.1.1.25 extracted from
- Kinetic and molecular dynamic studies of inhibitors of shikimate dehydrogenase from methicillin-resistant Staphylococcus aureus (2019), Chem. Biol. Drug Des., 94, 1504-1517 .
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 1,3-benzodioxole-5-carbothioamide | the compound shows higher affinity for the shikimate binding site than for the NADP+ binding site, mixed full inhibition mechanism versus shikimate, non-competitive full inhibition mechanism versus NADP+, interaction analysis and enzyme-bound structure, overview. 75% inhibition at 0.4 mM | Staphylococcus aureus |  |
| 5-[4-(1H-imidazol-2-ylcarbonyl)phenyl]thiophene-2-carboxylic acid | the compound shows higher affinity for the shikimate binding site than for the NADP+ binding site, uncompetitive full inhibition versus shikimate and mixed full inhibition versus NADP+, interaction analysis and enzyme-bound structure, overview. 98% inhibition at 0.4 mM | Staphylococcus aureus | |
| 6-(2,6-dichlorophenoxy) pyridin-3-amine | 60% inhibition at 0.4 mM | Staphylococcus aureus | |
| 6-amino-1,2,3,4-tetrahydronaphthalen-1-one | the compound presents a higher affinity for NADP+ binding site than for shikimate binding, mixed partial inhibition mechanism versus NADP+ and mixed full versus shikimate, interaction analysis and enzyme-bound structure, overview. 91% inhibition at 0.4 m | Staphylococcus aureus | |
| 6-hydroxy-1-benzofuran-3(2H)-one | - |
Staphylococcus aureus | |
| 6-hydroxy-7-methyl-1-benzofuran-3(2H)-one | mixed partial inhibition mechanism versus NADP+ and shikimate, interaction analysis and enzyme bound structure, overview. 98% inhibition at 0.4 mM | Staphylococcus aureus | |
| 7-hydroxy-2,2,8-trimethyl-2,3-dihydro-4H-1-benzopyran-4-one | - |
Staphylococcus aureus | |
| cyclopropyl(5-hydroxy-1-benzofuran-3-yl)methanone | 32% inhibition at 0.4 mM | Staphylococcus aureus | |
| ethyl 5-(1H-pyrazol-3-yl)thiophene-2-carboxylate | 28% inhibition at 0.4 mM | Staphylococcus aureus | |
| additional information | structure-based inhibitor design, small-molecule library screening, inhibition mechanism analysis | Staphylococcus aureus | |
| N-methyl-N-(quinolin-6-ylmethyl)amine | 63% inhibition at 0.4 mM | Staphylococcus aureus | |
| N-[2,2-dimethyl-6-(1-methyldioxidan-1-ium-1-yl)-3,4-dihydro-2H-1-benzopyran-4-yl]-N2-methyl-N2-[(pyridin-2-yl)methyl]glycinamide | 34% inhibition at 0.4 mM | Staphylococcus aureus | |
| [2,2'-bithiophene]-5-carboxylic acid | - |
Staphylococcus aureus | |
| [4-(4-methylperhydro-1,4-diazepin-1-yl)phenyl]methanol | 67% inhibition at 0.4 mM | Staphylococcus aureus | |
KM Value [mM]
| KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|
| additional information | - |
additional information | Michaelis-Menten kinetics | Staphylococcus aureus |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| shikimate + NADP+ | Staphylococcus aureus | - |
3-dehydroshikimate + NADPH + H+ | - |
r | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Staphylococcus aureus | - |
MRSA | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| shikimate + NADP+ | - |
Staphylococcus aureus | 3-dehydroshikimate + NADPH + H+ | - |
r | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| SaSDH | - |
Staphylococcus aureus |
| SDH | - |
Staphylococcus aureus |
| shikimate dehydrogenase | - |
Staphylococcus aureus |
Temperature Optimum [°C]
| Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 25 | - |
NADP+ reduction assay at | Staphylococcus aureus |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 8 | - |
NADP+ reduction assay at | Staphylococcus aureus |
Cofactor
| Cofactor | Comment | Organism | Structure |
|---|---|---|---|
| NADP+ | - |
Staphylococcus aureus | |
| NADPH | - |
Staphylococcus aureus | |
Ki Value [mM]
| Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
|---|---|---|---|---|---|
| additional information | - |
additional information | inhibition kinetics and mechanisms, molecular dynamics simulation, overview | Staphylococcus aureus | |
| 0.0083 | - |
[4-(4-methylperhydro-1,4-diazepin-1-yl)phenyl]methanol | pH 8.0, 25°C, versus NADP+ | Staphylococcus aureus | |
| 0.0103 | - |
[4-(4-methylperhydro-1,4-diazepin-1-yl)phenyl]methanol | pH 8.0, 25°C, versus shikimate | Staphylococcus aureus | |
| 0.046 | - |
6-amino-1,2,3,4-tetrahydronaphthalen-1-one | pH 8.0, 25°C, versus NADP+ | Staphylococcus aureus | |
| 0.075 | - |
1,3-benzodioxole-5-carbothioamide | pH 8.0, 25°C, versus shikimate | Staphylococcus aureus | |
| 0.083 | - |
5-[4-(1H-imidazol-2-ylcarbonyl)phenyl]thiophene-2-carboxylic acid | pH 8.0, 25°C, versus shikimate | Staphylococcus aureus | |
| 0.101 | - |
6-amino-1,2,3,4-tetrahydronaphthalen-1-one | pH 8.0, 25°C, versus shikimate | Staphylococcus aureus | |
| 0.213 | - |
5-[4-(1H-imidazol-2-ylcarbonyl)phenyl]thiophene-2-carboxylic acid | pH 8.0, 25°C, versus NADP+ | Staphylococcus aureus | |
| 0.246 | - |
1,3-benzodioxole-5-carbothioamide | pH 8.0, 25°C, versus NADP+ | Staphylococcus aureus | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
